Please login to the form below
risankizumab
This page shows the latest risankizumab news and features for those working in and with pharma, biotech and healthcare.
New data keeps AbbVie’s star pipeline therapies on track
New data keeps AbbVie’ s star pipeline therapies on track. Data showed 56% of patients on risankizumab were symptom free after a year’s treatment. ... The analysis showed that 56% of patients on risankizumab were symptom-free after a year’s
Latest news
-
BMS psoriasis drug hits the mark in phase II
including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.
-
Boehringer beefs up biologics capacity with €230m investment
That includes its portfolio of biosimilar drugs, as well as novel candidates such as AbbVie-partnered interleukin-23 inhibitor risankizumab – in phase III trials in psoriasis and psoriatic arthritis – and
-
Boehringer beefs up biologics capacity with €230m investment
That includes its portfolio of biosimilar drugs, as well as novel candidates such as AbbVie-partnered interleukin-23 inhibitor risankizumab – in phase III trials in psoriasis and psoriatic arthritis – and
-
UK, Germany back routine use of J&J’s Tremfya
J&J is facing the threat of direct competition to Tremfya, however, as rival AbbVie’s IL-23 inhibitor risankizumab which - according to some analysts - might have an edge in terms
-
AbbVie’s upadacitinib aces phase III trial
One of those new hopefuls - Rova-T for lung cancer - failed in trials but upadacitinib and anti-IL-23 antibody risankizumab (ABBV-066) remain on track after the latter reported positive
More from news
Approximately 3 fully matching, plus 7 partially matching documents found.
Featured jobs
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Associate Medical Director
-
Salary TBC
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
Account Director
-
Negotiable
-
Scientific Team Lead
-
Competitive Salary
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
- Director Healthcare PR Communications
-
Salary TBC
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
-
Scientific Director
-
Highly Competitive Salary &Benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Account Director - Digital
-
Great salary and benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Experienced Editor, London, Medical Communications
-
Competitive package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Associate Medical Director
-
Highly Competitive
- Account Director – Global Healthcare PR
-
Salary TBC
Subscribe to our email news alerts
- Merck’s Bavencio joins first-line kidney cancer face-off
- Encouraging data for GenSight’s blinding retinal disease gene therapy
- Lonely planet: why there is dwindling value in pharma travelling alone
- AZ and Clovis PARP inhibitors show their mettle at ESMO
- AZ and Medicines Catapult collaborate on innovative sound tech in drug discovery
- Dynavax is ‘deal-ready’ after solid ESMO data; analyst
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Retaining reader value in plain language summaries of clinical studies
- Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
- Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
- Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe's leading hub for life sciences innovation...
Quick links
Infographics
